基于机器学习的非侵入性帕金森病诊断模型,使用临床血液生物标志物
Jiaqi Han1, Mengge Sun2, Ji Yang3
1Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Shanghai, 200123, China. hanqiushu@126.com.
概括
使用血液生物标志物的机器学习模型可以有效地诊断帕金森病 (PD). 这项研究确定了超氧化物脱酶 (SOD) 作为PD诊断和严重程度的关键指标.
科学领域:
- 生物医学工程 生物医学工程
- 计算生物学 计算生物学
- 神经学 神经学
背景情况:
- 帕金森病 (PD) 诊断缺乏可靠的非侵入性标志物,阻碍了早期检测和治疗.
- 与血液生物标志物集成的机器学习 (ML) 为早期PD诊断和监测提供了潜在的解决方案.
研究的目的:
- 开发和验证使用ML和常规血液生物标志物的PD非侵入性诊断模型.
- 确定与PD严重程度相关的关键生物标志物.
主要方法:
- 利用来自两个医疗中心的920名参与者 (428名PD,492名非PD) 的数据进行培训和验证.
- 采用LASSO和阶段回归来选择生物标志物,并构建/比较了五个ML模型 (LR,SVM,DT,NB,KNN).
- 使用Shapley值 (SHAP) 解释了最佳模型,并评估了与PD严重程度 (Hoehn-Yahr阶段) 的相关性.
主要成果:
- 支持矢量机 (SVM) 模型实现了高的外部验证性能 (AUC=0.916,回忆=0.949,F1分数=0.843).
- 在SHAP分析中,超氧化物脱酶 (SOD) 是最有影响力的预测因子,其次是性别和尿酸 (UA).
- 白蛋白 (ALB) 和SOD水平与PD严重程度有负相关性.
结论:
- 基于SVM的模型在区分PD与使用可访问的临床生物标志物的对照中表现出高效率.
- 这种方法显示了PD查,诊断和监测疾病进展的临床应用的巨大潜力.
相关概念视频
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


